VistaGen Therapeutics
Yahoo Finance • 2 months ago
VistaGen Therapeutics Inc Q1 Sales Increase
(RTTNews) - VistaGen Therapeutics Inc (VTGN) announced Loss for first quarter of -$15.10 million The company's bottom line came in at -$15.10 million, or -$0.47 per share. This compares with -$10,73 million, or -$0.35 per share, last yea... Full story
Yahoo Finance • 4 months ago
Vistagen appoints Elissa Cote as Chief Corporate Development Officer
SOUTH SAN FRANCISCO - Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company with a market capitalization of approximately $61 million, has appointed Elissa Cote as Chief Corporate Development Officer, according to a press... Full story
Yahoo Finance • 4 months ago
Stifel reiterates buy rating on VistaGen stock amid clinical progress
Stifel maintained its buy rating and $12.00 price target on VistaGen Therapeutics (NASDAQ:VTGN) following the company’s fiscal year 2025 update. Currently trading at $2.16, the stock appears undervalued according to InvestingPro analysis.... Full story
Yahoo Finance • 4 months ago
Earnings call transcript: Vistagen's focus on innovation amid rising expenses Q1 2025
Vistagen Therapeutics held its Q1 2025 earnings call, highlighting increased research and development expenses and a strategic focus on its innovative pipeline. Despite a net loss of $51.4 million, the company remains committed to advancin... Full story
Yahoo Finance • 4 months ago
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of this year PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026 Company show... Full story
Yahoo Finance • 3 years ago
Vistagen to Participate in Upcoming Morgan Stanley and Baird Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., September 09, 2022--(BUSINESS WIRE)--Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua... Full story
Yahoo Finance • 3 years ago
2 “Strong Buy” Penny Stocks That Could Go Boom
Between the Fed's aggressive policy tightening to rein in inflation and deteriorating economic data, volatility has become a seemingly ever-present facet of the stock market. While the current economic landscape has spurred fear among inve... Full story
Yahoo Finance • 3 years ago
VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update
Completed last patient out milestone for PALISADE-1 Phase 3 clinical trial of PH94B in social anxiety disorder (SAD). Topline results for PALISADE-1 anticipated mid-2022. PALISADE-2 on track for topline readout in late 2022. Received FDA c... Full story
